These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20206671)

  • 1. Concomitant administration of recombinant PsaA and PCV7 reduces Streptococcus pneumoniae serotype 19A colonization in a murine model.
    Whaley MJ; Sampson JS; Johnson SE; Rajam G; Stinson-Parks A; Holder P; Mauro E; Romero-Steiner S; Carlone GM; Ades EW
    Vaccine; 2010 Apr; 28(18):3071-5. PubMed ID: 20206671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae.
    Dagan R
    Clin Microbiol Infect; 2009 Apr; 15 Suppl 3():16-20. PubMed ID: 19366365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post hoc analysis of a randomized double-blind trial of the correlation of functional and binding antibody responses elicited by 13-valent and 7-valent pneumococcal conjugate vaccines and association with nasopharyngeal colonization.
    Juergens C; Patterson S; Trammel J; Greenberg D; Givon-Lavi N; Cooper D; Gurtman A; Gruber WC; Scott DA; Dagan R
    Clin Vaccine Immunol; 2014 Sep; 21(9):1277-81. PubMed ID: 24990907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
    Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
    Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
    Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
    Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of pneumococcal carriage in mice by subcutaneous immunization with peptides from the common surface protein pneumococcal surface adhesin a.
    Johnson SE; Dykes JK; Jue DL; Sampson JS; Carlone GM; Ades EW
    J Infect Dis; 2002 Feb; 185(4):489-96. PubMed ID: 11865401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers.
    Dagan R; Givon-Lavi N; Zamir O; Sikuler-Cohen M; Guy L; Janco J; Yagupsky P; Fraser D
    J Infect Dis; 2002 Apr; 185(7):927-36. PubMed ID: 11920317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with streptococcus pneumoniae in children in Calgary, Canada.
    Kellner JD; Scheifele D; Vanderkooi OG; Macdonald J; Church DL; Tyrrell GJ
    Pediatr Infect Dis J; 2008 Jun; 27(6):526-32. PubMed ID: 18458650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenic protein contaminants in pneumococcal vaccines.
    Yu J; Briles DE; Englund JA; Hollingshead SK; Glezen WP; Nahm MH
    J Infect Dis; 2003 Mar; 187(6):1019-23. PubMed ID: 12660950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine.
    Millar EV; O'Brien KL; Bronsdon MA; Madore D; Hackell JG; Reid R; Santosham M
    Clin Infect Dis; 2007 May; 44(9):1173-9. PubMed ID: 17407035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and immunogenicity of capsular polysaccharide-surface adhesin A (PsaA) conjugate of Streptococcuspneumoniae.
    Lin H; Lin Z; Meng C; Huang J; Guo Y
    Immunobiology; 2010 Jul; 215(7):545-50. PubMed ID: 19880214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members.
    Millar EV; Watt JP; Bronsdon MA; Dallas J; Reid R; Santosham M; O'Brien KL
    Clin Infect Dis; 2008 Oct; 47(8):989-96. PubMed ID: 18781875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.
    Miernyk KM; Butler JC; Bulkow LR; Singleton RJ; Hennessy TW; Dentinger CM; Peters HV; Knutsen B; Hickel J; Parkinson AJ
    Clin Infect Dis; 2009 Jul; 49(2):241-8. PubMed ID: 19522655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.
    Lin PL; Michaels MG; Green M; Mazariegos GV; Webber SA; Lawrence KS; Iurlano K; Greenberg DP
    Pediatrics; 2005 Jul; 116(1):160-7. PubMed ID: 15995047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal immunization with PsaA protein, using chitosan as a delivery system, increases protection against acute otitis media and invasive infection by Streptococcus pneumoniae.
    Xu JH; Dai WJ; Chen B; Fan XY
    Scand J Immunol; 2015 Mar; 81(3):177-85. PubMed ID: 25565478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of conjugate vaccine on transmission of antimicrobial-resistant Streptococcus pneumoniae among Alaskan children.
    Park SY; Moore MR; Bruden DL; Hyde TB; Reasonover AL; Harker-Jones M; Rudolph KM; Hurlburt DA; Parks DJ; Parkinson AJ; Schuchat A; Hennessy TW
    Pediatr Infect Dis J; 2008 Apr; 27(4):335-40. PubMed ID: 18316986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.